British Journal of Haematology

Journal

Publication Venue For

  • Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin.  187:e51-e54. 2019
  • Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.  186:807-819. 2019
  • Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.  186:367-370. 2019
  • A population-based analysis of second primary malignancies in T-cell neoplasms.  185:338-342. 2019
  • Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.  185:169-174. 2019
  • T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.  185:140-142. 2019
  • Incidence and outcomes of rare paediatric non-hodgkin lymphomas.  184:864-867. 2019
  • Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.  184:674-676. 2019
  • Revisiting fat embolism in sickle syndromes: diagnostic and emergency therapeutic measures.  186:e112-e115. 2019
  • Efficacy of biological agents in the treatment of Erdheim-Chester disease.  183:520-524. 2018
  • Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.  182:579-581. 2018
  • Second primary malignancy after multiple myeloma-population trends and cause-specific mortality.  182:513-520. 2018
  • Incidence and survival trends in mantle cell lymphoma.  181:703-706. 2018
  • Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.  181:145-148. 2018
  • Incidence and outcomes of paediatric myelodysplastic syndrome in the United States.  180:898-901. 2018
  • R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.  180:534-544. 2018
  • Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.  179:843-846. 2017
  • Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel.  175:588-601. 2016
  • Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.  175:55-65. 2016
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: Further results of the E1905 North American Leukemia Intergroup study.  172:384-391. 2016
  • Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.  171:411-416. 2015
  • Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis.  170:859-873. 2015
  • Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.  170:574-583. 2015
  • Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study.  169:534-543. 2015
  • Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.  169:219-227. 2015
  • REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.  168:796-805. 2015
  • Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.  167:62-68. 2014
  • Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.  166:352-359. 2014
  • Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.  163:205-213. 2013
  • Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens..  162:376-382. 2013
  • Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: A report from the Southern Network on Adverse Reactions (SONAR).  161:896-898. 2013
  • Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).  160:538-546. 2013
  • Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: A phase I study.  162:693-701. 2013
  • Human immunodeficiency virus associated thrombotic thrombocytopenic purpura - favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.  153:515-519. 2011
  • ICA-17043-10 Study Investigators. Improvements in Haemolysis and Indicators of Erythrocyte Survival Do Not Correlate with Acute Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase III Randomized, Placebo-Controlled, Double-Blind Study of the Gardos Channel Blocker Senicapoc (ICA-17043)..  153:92-104. 2011
  • Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure.  151:94-96. 2010
  • Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.  148:48-58. 2010
  • Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.  146:576-577. 2009
  • Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.  144:930-932. 2009
  • Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.  143:268-273. 2008
  • Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.  142:404-412. 2008
  • Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation.  142:11-26. 2008
  • Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation.  141:827-839. 2008
  • The MLL partial tandem duplication in acute myeloid leukaemia.  135:438-449. 2006
  • Histamine increases sickle erythrocyte adherence to endothelium.  132:512-522. 2006
  • A serine-rich glycoprotein of Streptococcus sanguis mediates adhesion to platelets via GPIb.  129:101-109. 2005
  • Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease.  127:585-591. 2004
  • Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.  125:470-476. 2004
  • A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells.  125:167-179. 2004
  • Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A study of the Cancer and Leukaemia Group B.  124:275-288. 2004
  • Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence.  122:345-359. 2003
  • Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.  118:799-808. 2002
  • Abnormal growth factor modulation of β1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors.  115:845-853. 2001
  • NON-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemias.  114:11-24. 2001
  • Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9.  104:365-373. 1999
  • V(H) gene usage by family members affected with chronic lymphocytic leukaemia.  107:616-624. 1999
  • Haemopoietic transformation by the TEL/ABL oncogene.  102:475-485. 1998
  • Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.  99:368-371. 1997
  • Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets.  68:47-51. 1988
  • Blood Coagulation Defects in Kwashiorkor and Infantile Gastroenteritis.  3:39-49. 1957
  • International Standard Serial Number (issn)

  • 0007-1048
  • Electronic International Standard Serial Number (eissn)

  • 1365-2141